HORIZON : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
• Zoledronic acid (Reclast) is approved for the reduction of vertebral, nonvertebral, and hip fractures (AACE).
• In the long-term extension study of HORIZON PFT, patients at high risk for fractures, who stopped ZA after 3 years instead of 6 years experienced a higher risk of fractures.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22.